Arman Arabshomali

Dr. Arman Arabshomali

Pharmacy Administration, University of Mississippi, Oxford, Alabama, USA
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2023 in Molecules
Verified
Journal Article
Open access
PDF file
AAArman Arabshomali
Arman Arabshomali
SBShadi Bazzazzadehgan
Shadi Bazzazzadehgan
FMFakhri Mahdi
Fakhri Mahdi
ZSZia Shariat-Madar
Zia Shariat-Madar
The clinical relationship between diabetes and inflammation is well established. Evidence clearly indicates that disrupting oxidant-antioxidant equilibrium and elevated lipid peroxidation could be a potential mechanism for chronic kidney disease associated with type 2 diabetes mellitus (T2DM). Under diabetic conditions, hyperglycemia, especially inflammation, and increased reactive oxygen species generation are bidirectionally associated. Inflammation, oxidative stress, and tissue damage are believed to play a role in the development of diabetes. Although the exact mechanism underlying oxidative stress and its impact on diabetes progression remains uncertain, the hyperglycemia-inflammation-oxidative stress interaction clearly plays a significant role in the onset and progression of vascular disease, kidney disease, hepatic injury, and pancreas damage and, therefore, holds promise as a therapeutic target. Evidence strongly indicates that the use of multiple antidiabetic medications fails to achieve the normal range for glycated hemoglobin targets, signifying treatment-resistant diabetes. Antioxidants with polyphenols are considered useful as adjuvant therapy for their potential anti-inflammatory effect and antioxidant activity. We aimed to analyze the current major points reported in preclinical, in vivo, and clinical studies of antioxidants in the prevention or treatment of inflammation in T2DM. Then, we will share our speculative vision for future diabetes clinical trials.

15 October 2024 in Molecules
Verified
Journal Article
Open access
PDF file
MSMasoud Salavati
Masoud Salavati
AAArman Arabshomali
Arman Arabshomali
Sasan NouranianSasan Nouranian
Sasan Nouranian
ZSZia Shariat-Madar
Zia Shariat-Madar
Venous thromboembolism (VTE) is a serious health condition and represents an important cause of morbidity and, in some cases, mortality due to the lack of effective treatment options. According to the Centers for Disease Control and Prevention, 3 out of 10 people with VTE will have recurrence of a clotting event within ten years, presenting a significant unmet medical need. For some VTE patients, symptoms can last longer and have a higher than average risk of serious complications; in contrast, others may experience complications arising from insufficient therapies. People with VTE are initially treated with anticoagulants to prevent conditions such as stroke and to reduce the recurrence of VTE. However, thrombolytic therapy is used for people with pulmonary embolism (PE) experiencing low blood pressure or in severe cases of DVT. New drugs are under development, with the aim to ensure they are safe and effective, and may provide an additional option for the treatment of VTE. In this review, we summarize all ongoing trials evaluating anticoagulant interventions in VTE listed in clinicaltrials.gov, clarifying their underlying mechanisms and evaluating whether they prevent the progression of DVT to PE and recurrence of thrombosis. Moreover, this review summarizes the available evidence that supports the use of antiplatelet therapy for VTE. Since thrombolytic agents would cause off-target effects, targeted drug delivery platforms are used to develop various therapeutics for thrombotic diseases. We discuss the recent advances achieved with thrombus-targeting nanocarriers as well as the major challenges associated with the use of nanoparticle-based therapeutics.

29 August 2025 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
SFSoroush Fariman
Soroush Fariman
AAArman Arabshomali
Arman Arabshomali
DGDarshna Goordeen
Darshna Goordeen
JNJoshua Niznik
Joshua Niznik
HHHoma Hemati
Homa Hemati
JLJennifer Elston Lafata
Jennifer Elston Lafata

24 April 2026 in Journal of Affective Disorders
Verified
Journal Article
Open access
KBKaustuv Bhattacharya
Kaustuv Bhattacharya
AAArman Arabshomali
Arman Arabshomali
LLLiang-Yuan Lin
Liang-Yuan Lin
SBShadi Bazzazzadehgan
Shadi Bazzazzadehgan
QPQueenie Paltanwale
Queenie Paltanwale
SGSwarnali Goswami
Swarnali Goswami
This study estimated the incremental burden of comorbid depression on healthcare resource utilization (HCRU) and costs, functional limitations, health-related quality of life (HRQoL), and missed workdays, among adults with irritable bowel syndrome (IBS). This cross-sectional study used 2016-2021 Medical Expenditure Panel Survey data to identify adults with IBS, with or without comorbid depression. The incremental effect of comorbid depression on HCRU was assessed using negative binomial models, while healthcare cost components were examined using generalized linear and two-part models. Functional limitations were assessed using logistic regression. Multivariable linear and negative binomial regression models were used to compare HRQoL (physical [PCS] and mental [MCS] component summary scores) and missed workdays, respectively, between groups. The sample included 1,422,146 (unweighted = 746) adults with IBS in the US, of whom 33.40% had depression. After adjusting for covariates, individuals with IBS and comorbid depression had significantly higher HCRU and costs across all categories than those without. Comorbid depression was significantly associated with greater odds of functional limitations. The mean MCS score was significantly lower among individuals with comorbid depression (mean difference: -14.80; 95% CI: -19.90 to -9.71), while no significant difference was observed in PCS. Individuals with comorbid depression reported 4.99 more missed workdays (95% CI: 4.64-5.36), compared to those without depression. Comorbid depression is associated with higher HCRU and costs, greater functional impairment, poorer mental HRQoL, and more missed workdays, among individuals with IBS. Targeted screening and better management of depression may improve outcomes in this population.

28 August 2026 in Health Affairs Scholar
Verified
Journal Article
Open access
SRSujith Ramachandran
Sujith Ramachandran
AAArman Arabshomali
Arman Arabshomali
JCJohn Coster
John Coster
This article examines the historical evolution of prescription drug pricing policy in the United States from the 1960s through 2025, highlighting how incremental reforms have produced a complex and fragmented system. It traces the foundations of drug pricing across Medicaid, Medicare, the Veterans Affairs (VA) system, and the 340B Drug Discount program, emphasizing the development of key pricing benchmarks such as Average Wholesale Price (AWP), Average Manufacturer Price (AMP), and Average Sales Price (ASP). The analysis details major legislative milestones affecting drug pricing, including the Omnibus Budget Reconciliation Act (OBRA) of 1990, the Medicare Modernization Act (MMA) of 2003, the Affordable Care Act (ACA) of 2010, and the Inflation Reduction Act (IRA) of 2022, and explains how these reforms reshaped reimbursement, rebates, cost of the prescription drugs, and access to medications. The article also identifies the various consequences of policy design, including the Medicaid “best price” provisions, growth in state Medicaid program supplemental rebates, and changes in prescription drug spending and reimbursement. Understanding the trajectory of policy reform is critical to identifying opportunities for improving affordability, access, and transparency in prescription drug markets.

26 September 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
AAArman Arabshomali
Arman Arabshomali
SBShadi Bazzazzadehgan
Shadi Bazzazzadehgan
FMFakhri Mahdi
Fakhri Mahdi
ZSZia Shariat-Madar
Zia Shariat-Madar
The clinical relationship between diabetes and inflammation is well-established. Various branches of science independently have confirmed that disrupting oxidant-antioxidant equilibrium and elevated lipid peroxidation could be a potential mechanism for chronic kidney disease associated with Type 2 diabetes mellitus (T2DM). Under diabetic condition, hyperglycemia, especially inflammation, and increased reactive oxygen species generation are bidirectionally associated. Inflammation, oxidative stress and tissue damage are believed to have a role in the development of diabetes. Although the exact mechanism underlying the oxidative stress and its impact on diabetes progression remains uncertain, the hyperglycemia-inflammation-oxidative stress interaction clearly plays a significant role in onset and progression of vascular disease, kidney disease, hepatic injury, pancreas damage and, therefore holds promise as a therapeutic target. Evidence strongly indicates that the use of multiple antidiabetic medications therapy fails to achieve the normal range for glycated hemoglobin target, signifying treatment resistant diabetes. Antioxidants with polyphenols are considered useful as adjuvant therapy for their potential anti-inflammatory effect and antioxidant activity. We aimed to analyze the current major points reported in preclinical in vivo and clinical studies of antioxidants in the prevention or treatment of inflammation in T2DM. Then, we will share our speculative vision of the future diabetes clinical trials.